Cao X, Wen Z-S, Sun Y-J, Li Y, Zhang L, Han Y-J
Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong 510060, China.
1] Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong 510060, China [2] Department of Surgical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, China.
Br J Cancer. 2014 Jul 8;111(1):174-80. doi: 10.1038/bjc.2014.302. Epub 2014 Jun 5.
Previous studies supported a link between the ABO blood type and survival for several types of malignancies. Nonetheless, the relationship between ABO blood type and survival in colon cancer patients has not been rigorously evaluated. The goal of this retrospective analysis was to discern the correlations between ABO blood group and colon cancer survival.
A total of 1555 colon cancer patients that underwent curative-intent surgery between October 1995 and June 2002 were eligible for this study. The primary outcomes measured were the association between ABO blood group and patient survival.
Compared with patients with non-AB blood types (blood types A, B, and O), patients with blood type AB were more likely to have better survival. The mean overall survival (OS) of the blood type AB patients was 113.9 months, whereas the mean OS of the non-AB blood type patients was significantly lower, 106.1 months (P<0.001, log-rank test). Compared with patients with blood type AB, the hazard ratios for patients with A, B, and O were 4.37 (95% confidence interval (95% CI), 2.65-7.20), 2.99 (95% CI, 1.81-4.96), and 2.78 (95% CI, 1.69-4.56), respectively.
Blood type AB is a favourable prognostic factor for patients with colon cancer.
先前的研究支持ABO血型与几种恶性肿瘤的生存率之间存在联系。尽管如此，ABO血型与结肠癌患者生存率之间的关系尚未得到严格评估。这项回顾性分析的目的是识别ABO血型与结肠癌生存率之间的相关性。
1995年10月至2002年6月期间接受根治性手术的1555例结肠癌患者符合本研究条件。所测量的主要结局是ABO血型与患者生存率之间的关联。
与非AB血型（A、B和O型血）患者相比，AB型血患者更有可能有更好的生存率。AB型血患者的平均总生存期（OS）为113.9个月，而非AB血型患者的平均OS显著更低，为106.1个月（P<0.001，对数秩检验）。与AB型血患者相比，A、B和O型血患者的风险比分别为4.37（95%置信区间（95%CI），2.65-7.20）、2.99（95%CI，1.81-4.96）和2.78（95%CI，1.69-4.56）。
AB型血是结肠癌患者的一个有利预后因素。
